Evidence map›Paper›PMID 41868609›Full record

ArticleLiver cancer2026

Machine Learning Models for Disease-Free Survival Analysis after Liver Resection for Hepatocellular Carcinoma: A Multicentric French Collaborative Study.

Rami Rhaiem, Ammar Abdo, Julien Calderaro, Safi Dokmak, Astrid Herrero, Cyprien Toubert, Perrine Zimmermann, Alexandra Heurgué, Camille Boulagnon-Rombi, Giuliana Amaddeo and 11 more

Abstract read
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Rami RhaiemDepartment of HPB and Oncological Digestive Surgery, Cabrol University Hospital, CHU de Reims, Reims, France.
Ammar AbdoIIAS - Institute of Artificial Intelligence in Health, CHU de Reims, Université de Reims Champagne-Ardenne, Reims, France.
Julien CalderaroResearch Team "Viruses, Hepatology, Cancer" INSERM Unit 955, IMRB, Créteil, France.
Safi DokmakDepartment of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, APHP, Hôpital Beaujon, DMU DIGEST, Clichy, France.
Astrid HerreroDivision of HBP Surgery and Transplantation, Department of Surgery, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, Montpellier, France.
Cyprien ToubertDivision of HBP Surgery and Transplantation, Department of Surgery, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, Montpellier, France.
Perrine ZimmermannDepartment of HPB and Oncological Digestive Surgery, Cabrol University Hospital, CHU de Reims, Reims, France.
Alexandra HeurguéUniversity Reims Champagne Ardenne, Reims, France.
Camille Boulagnon-RombiUniversity Reims Champagne Ardenne, Reims, France.
Giuliana AmaddeoResearch Team "Viruses, Hepatology, Cancer" INSERM Unit 955, IMRB, Créteil, France.
Alain LucianiUniversité Paris-Est Créteil, UPEC, Paris, France.
Hélène RegnaultResearch Team "Viruses, Hepatology, Cancer" INSERM Unit 955, IMRB, Créteil, France.
Marie AlauxDivision of HBP Surgery and Transplantation, Department of Surgery, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, Montpellier, France.
Mickael LesurtelDepartment of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, APHP, Hôpital Beaujon, DMU DIGEST, Clichy, France.
Valérie ParadisUniversité de Paris, INSERM U1149, Hôpital Beaujon, Pathology Department, Hôpital Beaujon, AP-HP, Clichy, France.
Daniele SommacaleResearch Team "Viruses, Hepatology, Cancer" INSERM Unit 955, IMRB, Créteil, France.
Olivier SoubraneDepartment of Digestive Surgery, Institut Mutualiste Montsouris, Paris, France.
Stefano CarusoResearch Team "Viruses, Hepatology, Cancer" INSERM Unit 955, IMRB, Créteil, France.
Rudy MerieuxIIAS - Institute of Artificial Intelligence in Health, CHU de Reims, Université de Reims Champagne-Ardenne, Reims, France.
Reza KianmaneshDepartment of HPB and Oncological Digestive Surgery, Cabrol University Hospital, CHU de Reims, Reims, France.
Raffaele BrustiaResearch Team "Viruses, Hepatology, Cancer" INSERM Unit 955, IMRB, Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Liver resection (LR) is a potentially curative treatment of hepatocellular carcinoma (HCC), but early recurrence rates remain high reaching as high as 70%. Accurate prediction of disease-free survival (DFS) after LR is crucial to optimize patients' selection for clinical trials evaluating adjuvant strategies. This study assessed machine learning (ML) models for predicting DFS after LR for HCC. Methods: A total of 663 patients who underwent LR between 2010 and 2020 in 3 French HPB referral centers were analyzed. Three ML models - random survival forest (RSF), gradient boosting survival (GBS), and fast survival support vector machine (FSSVM) - were compared with the Cox proportional hazards regression model. Model performance was assessed using C-index and time-dependent area under the curve (AUC). External validation was performed using an independent cohort from a fourth center. Statistical comparisons between models were conducted using paired Results: After a median follow up of 52 months, recurrence occurred in 43% of patients and median DFS was 15 months. In the training cohort, RSF achieved the highest discrimination (C-index = 0.721 ± 0.027) and predictive accuracy (AUC = 0.768 ± 0.039) among the four evaluated models. Cox, GBS, and FSSVM showed comparable performance (C-index = 0.684-0.699; AUC = 0.718-0.745). Paired Conclusions: RSF significantly improved DFS prediction compared with Cox regression and yielded the best discriminatory performance in both training and external validation cohorts. These findings highlight the value of ML-based survival models, particularly RSF, for enhancing individualized postoperative prognostication and refining patient selection for clinical trials evaluating adjuvant treatment to surveillance after LR for HCC.

Indexed as

Hepatocellular carcinomaLiver resectionRecurrenceSurvival

Identifiers

PMID41868609
PMCPMC13004632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.